Archive for NIDA

Syntrix Clinical Trial of Omnitram Succeeds on Primary Endpoints

Syntrix announced that the Phase 1B study investigating Omnitram for pain in healthy subjects met its primary endpoints for pharmacokinetics, safety, and analgesia.  The study was performed with Syntrix collaborators at PRA International and the IIT Research Institute.  The study was funded by a $1.8 million grant from the National Institute on Drug Abuse (NIDA) […]

Syntrix Receives $1.8M Grant to Develop Omnitram for Acute and Chronic Pain

Congratulations to Syntrix scientists on their new grant for $1.8M from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The project title is “Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers.” Here is the public health relevance from the proposal: “Tramadol is a widely prescribed analgesic, but 10% of the U.S. population is resistant […]